恢复期血浆对重症COVID-19患者无器官支持天数的影响:一项随机临床试验
REMAP-CAP平台试验在129个中心随机2011例重症COVID-19成人,比较2单位高滴度ABO相容恢复期血浆(n=1084)与不输血浆(n=916)。主要终点21天内无器官支持天数中位数分别为0天与3天,校正OR 0.97(95%CrI 0.83-1.15),无效后验概率99.4%,因预设无效标准提前终止。院内死亡率37.3% vs 38.4%,严重不良事件3.0% vs 1.3%。结论:重症COVID-19患者输注恢复期血浆获益可能性低。
要点
- 重症COVID-19成人随机接受2单位高滴度ABO相容恢复期血浆,21天无器官支持天数中位数0天 vs 不输血浆3天。
- 校正OR 0.97(95%CrI 0.83-1.15),无效后验概率99.4%,因预设无效标准提前终止干预。
- 院内死亡率恢复期血浆组37.3%(401/1075) vs 不输血浆组38.4%(347/904),无获益信号。
- 严重不良事件恢复期血浆组3.0%(32/1075) vs 不输血浆组1.3%(12/905),需警惕输血相关不良事件。
- 主要终点与11项次要终点治疗效应一致,不支持重症COVID-19常规使用恢复期血浆。
适用人群与场景
- 疑似或确诊COVID-19的成人重症患者,随机时中位年龄61岁(IQR 52-70),女性645/1998(32.3%)。
- 纳入REMAP-CAP免疫球蛋白域,于2020年3月9日至2021年1月18日在4国129个中心随机。
诊断标准与关键阈值
- 主要终点为21天内无器官支持天数(存活且无需ICU器官支持的天数,范围-1至21天,死亡记为-1天)。
- 优效性定义为OR>1的后验概率>99%;无效定义为OR<1.2的后验概率>95%,达到后者即停止干预。
处置流程与药物剂量
- 恢复期血浆组:随机后48小时内输注2单位高滴度、ABO相容恢复期血浆,总容量550 mL±150 mL。
- 对照组:不输注恢复期血浆。
红旗征与不能漏的情况
- 严重不良事件恢复期血浆组3.0%(32/1075) vs 不输血浆组1.3%(12/905),原文未列出具体事件类型。
- 原文未提及其他需立即处理或不能漏诊的情况。
研究设计与关键结果
- 研究类型:随机、嵌入、多因素、适应性平台试验(REMAP-CAP)的免疫球蛋白域,开放标签干预。
- 样本量与中心:2011例重症成人随机(恢复期血浆n=1084,不输血浆n=916),129个中心,4个国家;1990例(99%)完成试验。
- 主要终点:21天无器官支持天数中位数恢复期血浆组0天(IQR -1至16) vs 不输血浆组3天(IQR -1至16);校正OR 0.97(95%CrI 0.83-1.15),无效后验概率99.4%。
- 次要终点:院内死亡率37.3%(401/1075) vs 38.4%(347/904);存活且无器官支持天数中位数14天(IQR 3-18) vs 14天(IQR 7-18);主要终点与11项次要终点效应一致。
- 不良事件:严重不良事件3.0%(32/1075) vs 1.3%(12/905)。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT),开放标签,贝叶斯累积逻辑模型分析。
- 因预设无效标准(OR<1.2后验概率>95%)达到而提前停止恢复期血浆干预。
- 局限性:开放标签设计;原文未提及其他局限。
对床旁实践的改变
- 重症COVID-19成人不应常规输注2单位高滴度ABO相容恢复期血浆以改善无器官支持天数。
- 该结论基于重症成人、随机后48小时内输注2单位高滴度ABO相容血浆的方案,不适用于非重症或其他血浆方案。
- 严重不良事件恢复期血浆组高于对照组(3.0% vs 1.3%),决策时需权衡输血相关风险。
指南或共识出处
- REMAP-CAP(Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia),ClinicalTrials.gov NCT02735707;发表于JAMA。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.
OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021.
INTERVENTIONS: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916).
MAIN OUTCOMES AND MEASURES: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events.
RESULTS: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group.
CONCLUSIONS AND RELEVANCE: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.
参考来源
- Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34606578. doi:10.1001/jama.2021.18178
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。